Thatch
A health-benefits platform that lets employers set healthcare budgets while employees choose insurance and eligible care to fit their needs.
$108MNew funding
ParticipantEL
Eli Lilly and Company
Activity from announced rounds
Activity in this selectionOct 22, 2026 · AI · Jul 25, 2026
Eli Lilly and Company is a medicines developer that also finances external innovation and provides laboratory and development resources to early biotechnology companies.
Its Catalyze360 platform combines several ways to work with a startup. Lilly Ventures provides investment; Lilly Gateway Labs provides laboratory facilities and scientific engagement; Lilly ExploR&D provides research and development capabilities.
The platform engages biotechs at the earliest stages across therapeutic areas. Its investment remit extends into new scientific platforms and health technology, giving founders routes to strategic capital and development infrastructure through different parts of Lilly’s external innovation organisation.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $168M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
Participant